GLP-1 compounding isn't dead yet, but the rules just changed

What did @realdrbae actually say?

The claim here is that Hims developed a "100% copycat pill" of oral semaglutide, changed nothing about it, and triggered FDA scrutiny that now threatens the entire compounding pharmacy industry. The creator frames it as corporate greed with collective consequences: Hims "got greedy" and brought "unwanted attention" to compounders everywhere. That framing is mostly accurate, but there are some details worth untangling before you repeat this at your next appointment.

The core story checks out. Hims & Hers did face regulatory pressure over its compounded oral semaglutide product. The FDA's concern was that the formulation appeared to be a direct copy of Novo Nordisk's Rybelsus, which is the FDA-approved oral semaglutide tablet, not Wegovy, which is injectable. That's a meaningful distinction the creator got wrong, and it matters for understanding the legal and clinical picture.

Does the science back this up?

Partly. Federal law under 503A and 503B compounding exemptions does allow pharmacies to prepare customized medications, but there's a specific prohibition: compounders cannot make a "copy" of a commercially available drug without a clinical difference that serves a specific patient need. That's not a technicality, it's a foundational rule.

Hims offered compounded oral semaglutide at a lower price point, which sounds patient-friendly. But the FDA's concern, consistent with its 2024 enforcement guidance on GLP-1 compounding, is that producing a functional copy of Rybelsus without meaningful modification potentially violates the drug compounding exemptions under the FD&C Act. There's no peer-reviewed trial proving compounded oral semaglutide is bioequivalent to Rybelsus, and the FDA has never sanctioned that equivalency claim. Patients and prescribers should know those are not interchangeable products in any regulatory or clinical sense.

What did they get wrong (or right)?

Credit where it's due: the general arc of the story is accurate. Hims pushed the boundaries of compounding law, attracted FDA attention, and that scrutiny has real downstream effects on the broader compounding industry. The phrase "unwanted attention" is an understatement, but directionally correct.

What's wrong: the creator repeatedly says Hims copied the "Wagovi pill." Wegovy is an injectable pen, not a pill. The oral GLP-1 product is Rybelsus, a different brand and formulation entirely. This isn't a minor slip. Conflating Wegovy and Rybelsus misrepresents how semaglutide is delivered, dosed, and absorbed. Oral and injectable semaglutide have different pharmacokinetic profiles. Rybelsus requires a specific fasting protocol and uses a special absorption enhancer called SNAC. These aren't trivial differences.

The creator also mispronounces Novo Nordisk as "Van Oordisc," which won't affect your health but does affect credibility.

What should you actually know?

The FDA's posture on GLP-1 compounding has been hardening since at least early 2024. When semaglutide was on the official drug shortage list, compounders had more latitude. As shortage designations were lifted, the FDA began issuing guidance restricting what's permissible. The Hims situation accelerated attention on oral formulations specifically.

If you are currently using compounded semaglutide from a legitimate 503A or 503B pharmacy, this doesn't automatically mean your access is ending tomorrow. But the regulatory window is narrowing. The FDA's 2024 and 2025 enforcement priorities signal that copycat formulations without clinical differentiation are the primary target. Compounders who add clinically justified additives or serve patients with documented needs for customized doses are in a legally different position than those making straight copies of brand-name drugs.

The creator's bottom line, that Hims acted recklessly and may have made things harder for everyone, is a reasonable read of the situation. The compounding industry has been lobbying hard to maintain access. Hims handing the FDA an obvious enforcement target did not help that cause.

What does this mean for patients seeking compounded GLP-1s?

Your compounded medication access depends on where your pharmacy sits legally. Patients working with regulated telehealth platforms that source from licensed 503B outsourcing facilities, or licensed 503A pharmacies with valid prescriptions, are not in the same boat as Hims. But watch this space. FDA enforcement actions tend to create chilling effects industry-wide, even when targeted at one bad actor. Ask your provider directly: what is the compounding pharmacy's license status, and does the formulation include any clinically justified modification? Those are the two questions that matter most right now.